Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2015, Article ID 973287, 12 pages
http://dx.doi.org/10.1155/2015/973287
Research Article

Combination Therapy with Oleanolic Acid and Metformin as a Synergistic Treatment for Diabetes

1National Drug Screening Center and Jiangsu Key Laboratory of TCM Evaluation and Translational Research, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, China
2Center for Drug Discovery, State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, China

Received 13 August 2014; Revised 13 December 2014; Accepted 15 December 2014

Academic Editor: Giuseppe Paolisso

Copyright © 2015 Xue Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. Paulweber, P. Valensi, J. Lindstr, N. M. Lalic, and C. J. Greaves, “Europe evidence-based guidline for the prevention of type 2 diabetes,” Hormone and Metabolic Research, vol. 42, supplement 1, pp. S3–S36, 2010. View at Google Scholar
  2. R. A. DeFronzo, D. Simonson, and E. Ferrannini, “Hepatic and peripheral insulin resistance: a common feature of Type 2 (non-insulin-dependent) and Type 1 (insulin-dependent) diabetes mellitus,” Diabetologia, vol. 23, no. 4, pp. 313–319, 1982. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Postic, R. Dentin, and J. Girard, “Role of the liver in the control of carbohydrate and lipid homeostasis,” Diabetes and Metabolism, vol. 30, no. 5, pp. 398–408, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. D. M. Nathan, J. B. Buse, M. B. Davidson, and et al, “Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes,” Diabetes Care, vol. 32, no. 3, pp. 193–203, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Foretz, S. Hébrard, J. Leclerc et al., “Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state,” The Journal of Clinical Investigation, vol. 120, no. 7, pp. 2355–2369, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. X. A. Wen, P. Zhang, J. Liu et al., “Pentacyclic triterpenes. Part 2: synthesis and biological evaluation of maslinic acid derivatives as glycogen phosphorylase inhibitors,” Bioorganic and Medicinal Chemistry Letters, vol. 16, no. 3, pp. 722–726, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Liu, H. Sun, W. Duan, D. Mu, and L. Zhang, “Maslinic acid reduces blood glucose in KK-Ay mice,” Biological and Pharmaceutical Bulletin, vol. 30, no. 11, pp. 2075–2078, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Liu, H. B. Sun, X. F. Wang, D. Mu, H. Liao, and L. Zhang, “Effects of oleanolic acid and maslinic acid on hyperlipidemia,” Drug Development Research, vol. 68, no. 5, pp. 261–266, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Chen, J. Liu, L. Zhang et al., “Pentacyclic triterpenes. Part 3: synthesis and biological evaluation of oleanolic acid derivatives as novel inhibitors of glycogen phosphorylase,” Bioorganic and Medicinal Chemistry Letters, vol. 16, no. 11, pp. 2915–2919, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Liu, T. He, Q. Lu, J. Shang, H. B. Sun, and L. Y. Zhang, “Asiatic acid preserves beta cell mass and mitigates hyperglycemia in streptozocin-induced diabetic rats,” Diabetes/Metabolism Research and Reviews, vol. 26, no. 6, pp. 448–454, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. L. Y. Zhang, J. Chen, Y. C. Gong, J. Liu, W. Hua, and H. Sun, “Synthesis and biological evaluation of asiatic acid derivatives as inhibitors of glycogen phosphorylases,” Chemistry & Biodiversity, vol. 6, no. 6, pp. 864–874, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. X. Wen, H. Sun, J. Liu et al., “Naturally occurring pentacyclic triterpenes as inhibitors of glycogen phosphorylase: synthesis, structure-activity relationships, and X-ray crystallographic studies,” Journal of Medicinal Chemistry, vol. 51, no. 12, pp. 3540–3554, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Liu, “Pharmacology of oleanolic acid and ursolic acid,” Journal of Ethnopharmacology, vol. 49, no. 2, pp. 57–68, 1995. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Liu, “Oleanolic acid and ursolic acid: research perspectives,” Journal of Ethnopharmacology, vol. 100, no. 1-2, pp. 92–94, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. P. Dzubak, M. Hajduch, D. Vydra et al., “Pharmacological activities of natural triterpenoids and their therapeutic implications,” Natural Product Reports, vol. 23, no. 3, pp. 394–411, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. L. Z. Xu and Z. X. Wan, “The effect of oleanolic acid on acute hepatitis (70 cases),” Humane Medicine, vol. 7, pp. 50–52, 1980. View at Google Scholar
  17. S. L. Xu, “Effects of oleanolic acid on chronic hepatitis: 188 case reports,” in Symposium on Oleanolic Acid, pp. 23–25, 1985.
  18. D. M. Minich, J. S. Bland, J. Katke et al., “Clinical safety and efficacy of NG440: a novel combination of rho iso-alpha acids from hops, rosemary, and oleanolic acid for inflammatory conditions,” Canadian Journal of Physiology and Pharmacology, vol. 85, no. 9, pp. 872–883, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. D. R. Matthews, J. P. Hosker, A. S. Rudenski, B. A. Naylor, D. F. Treacher, and R. C. Turner, “Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man,” Diabetologia, vol. 28, no. 7, pp. 412–419, 1985. View at Publisher · View at Google Scholar · View at Scopus
  20. R. D. Lillie and J. Greco, “Malt diastase and ptyalin in place of saliva in the identification of glycogen,” Biotechnic & Histochemistry, vol. 22, no. 2, pp. 67–70, 1947. View at Publisher · View at Google Scholar
  21. N. Wollen and C. J. Bailey, “Inhibition of hepatic gluconeogenesis by metformin. Synergism with insulin,” Biochemical Pharmacology, vol. 37, no. 22, pp. 4353–4358, 1988. View at Publisher · View at Google Scholar · View at Scopus
  22. X. Wang, X.-L. Ye, R. Liu et al., “Antioxidant activities of oleanolic acid in vitro: possible role of Nrf2 and MAP kinases,” Chemico-Biological Interactions, vol. 184, no. 3, pp. 328–337, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. X. Wang, Y.-L. Li, H. Wu et al., “Antidiabetic effect of oleanolic acid: a promising use of a traditional pharmacological agent,” Phytotherapy Research, vol. 25, no. 7, pp. 1031–1040, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. P. S. Ngubane, B. Masola, and C. T. Musabayane, “The effects of syzygium aromaticum-derived oleanolic acid on glycogenic enzymes in streptozotocin-induced diabetic rats,” Renal Failure, vol. 33, no. 4, pp. 434–439, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. K. Sharma, P. McCue, and S. R. Dunn, “Diabetic kidney disease in the db/db mouse,” The American Journal of Physiology—Renal Physiology, vol. 284, no. 6, pp. 1138–1144, 2003. View at Google Scholar · View at Scopus
  26. K. S. Oh, E. Y. Kim, M. Yoon, and C. M. Lee, “Swim training improves leptin receptor deficiency-induced obesity and lipid disorder by activating uncoupling proteins,” Experimental and Molecular Medicine, vol. 39, no. 3, pp. 385–394, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. N. Ghilardi, S. Ziegler, A. Wiestner, R. Stoffel, M. H. Heim, and R. C. Skoda, “Defective STAT signaling by the leptin receptor in diabetic mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 13, pp. 6231–6235, 1996. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Chandran, F. Yap, and K. Hussain, “Molecular mechanisms of protein induced hyperinsulinaemichypoglycaemia,” World Journal of Diabetes, vol. 5, no. 5, pp. 666–677, 2014. View at Publisher · View at Google Scholar
  29. T. Pelikánová, “Insulin resistance—its causes and therapy possibilities,” Vnitrní Lékarství, vol. 60, no. 9, pp. 746–755, 2014. View at Google Scholar
  30. L. Agius, “Physiological control of liver glycogen metabolism: lessons from novel glycogen phosphorylase inhibitors,” Mini-Reviews in Medicinal Chemistry, vol. 10, no. 12, pp. 1175–1187, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. N. Gaboriaud-Kolar and A.-L. Skaltsounis, “Glycogen phosphorylase inhibitors: a patent review (2008–2012),” Expert Opinion on Therapeutic Patents, vol. 23, no. 8, pp. 1017–1032, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. J. C. Hutton and R. M. O'Brien, “Glucose-6-phosphatase catalytic subunit gene family,” The Journal of Biological Chemistry, vol. 284, no. 43, pp. 29241–29245, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. D. Stapleton, K. I. Mitchelhill, G. Gao et al., “Mammalian AMP-activated protein kinase subfamily,” The Journal of Biological Chemistry, vol. 271, no. 2, pp. 611–614, 1996. View at Publisher · View at Google Scholar · View at Scopus
  34. A. Woods, P. C. F. Cheung, F. C. Smith et al., “Characterization of AMP-activated protein kinase β and γ subunits: assembly of the heterotrimeric complex in vitro,” The Journal of Biological Chemistry, vol. 271, no. 17, pp. 10282–10290, 1996. View at Publisher · View at Google Scholar · View at Scopus
  35. W. W. Winder and D. G. Hardie, “Inactivation of acetyl-CoA carboxylase and activation of AMP-activated protein kinase in muscle during exercise,” The American Journal of Physiology—Endocrinology and Metabolism, vol. 270, no. 2, pp. E299–E304, 1996. View at Google Scholar · View at Scopus
  36. E. Hajduch, G. J. Litherland, and H. S. Hundal, “Protein kinase B (PKB/Akt)—a key regulator of glucose transport?” FEBS Letters, vol. 492, no. 3, pp. 199–203, 2001. View at Publisher · View at Google Scholar · View at Scopus
  37. E. Sarnowska, A. Balcerak, M. Olszyna-Serementa, D. Kotlarek, T. J. Sarnowski, and J. A. Siedlecki, “Amp-activated protein kinase (AMPK) as therapeutic target,” Postępy Higieny i Medycyny Doświadczalnej, vol. 67, pp. 750–760, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. A. R. Aroor, S. McKarns, V. G. Demarco, G. Jia, and J. R. Sowers, “Maladaptive immune and inflammatory pathways lead to cardiovascular insulin resistance,” Metabolism: Clinical and Experimental, vol. 62, no. 11, pp. 1543–1552, 2013. View at Publisher · View at Google Scholar · View at Scopus